Clinical Trials Medical Discoveries Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule By Helus Pharma Jul 21, 2026 Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program
Clinical Trials Medical Discoveries Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule By Helus Pharma Jul 21, 2026 Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program
Investments Opinions A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening By USA News Group Jul 21, 2026 Issued on behalf of Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP)
Investments Opinions A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening By USA News Group Jul 21, 2026 Issued on behalf of Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP)
Investments Opinions Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time By USA News Group Jul 17, 2026 Issued on behalf of Helus Pharma™
Investments Opinions Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time By USA News Group Jul 17, 2026 Issued on behalf of Helus Pharma™
Investments Opinions A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year By USA News Group Jun 26, 2026 Issued on behalf of Helus Pharma™
Investments Opinions A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year By USA News Group Jun 26, 2026 Issued on behalf of Helus Pharma™
